More on VERA
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $35.01 |
|
|||
| Open | $35.96 | ||||
| 52 Wk High | $1.18 | ||||
| 52 Wk Low | $0.36 | ||||
| Day High | $36.67 | ||||
| Day Low | $34.58 | ||||
| P/E | 584.83 | ||||
| EPS | $0.06 | ||||
| Volume | 1,497,554 | ||||
- Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Jefferies Reiterates Buy Rating on Vera Therapeutics (VERA)
- William Blair on Vera Therapeutics (VERA): 'We believe this update has positive read-through to companies developing novel therapies for IgAN'
- Wolfe Research: 'VERA's continued weakness is creating a favorable setup into the July 7th PDUFA'
- Goldman Sachs on Vera Therapeutics (VERA): 'We are encouraged by today's update'
- Raymond James: ''If Vera is successful with this new plan, it could effectively shorten the theoretical lead Otsuka'
- TD Cowen on Vera Therapeutics (VERA): 'Launch prep remains on track; we have confidence in a clean approval'
- Form 8-K Vera Therapeutics, Inc. For: Jun 02
- Vera Therapeutics moves up atacicept analysis timeline with FDA agreement
- Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy
Entities mentioned with VERA
- FDA | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Cowen & Co | View Related Stories »
- JPMorgan | View Related Stories »
- Earnings | View Related Stories »
- 13G | View Related Stories »
- Show More...
